Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-08-20
2010-11-30
Aulakh, Charanjit S (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S361500, C546S119000, C544S262000, C514S258100, C514S303000
Reexamination Certificate
active
07842712
ABSTRACT:
The present invention provides compounds of formula I:These compounds, and pharmaceutically acceptable compositions thereof, are useful generally as kinase inhibitors, particularly as inhibitors of PRAK, GSK3, ERK2, CDK2, MK2, SRC, SYK, and Aurora-2. Accordingly, compounds and compositions of the invention are useful for treating or lessening the severity of a variety of disorders, including, but not limited to, heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, allergic diseases, autoimmune diseases, destructive bone disorders such as osteoporosis, proliferative disorders, infectious diseases and viral diseases.
REFERENCES:
patent: 3486894 (1969-12-01), Coraluppi, et al.
patent: 3816121 (1974-06-01), Shiba et al.
patent: 2533958 (1977-02-01), None
patent: 0075808 (1983-04-01), None
patent: 1199306 (2002-04-01), None
patent: 1256574 (2002-11-01), None
patent: 1380576 (2004-01-01), None
patent: 1516610 (1968-03-01), None
patent: 3-179345 (1991-08-01), None
patent: 3-150560 (2001-06-01), None
patent: 2001354511 (2001-12-01), None
patent: 9824771 (1998-06-01), None
patent: 02062795 (2002-08-01), None
patent: 03024962 (2003-03-01), None
patent: 03040096 (2003-05-01), None
patent: 03063797 (2003-08-01), None
patent: 03068743 (2003-08-01), None
patent: 03078402 (2003-09-01), None
Cui et al. “Non-covalent Thrombin Inhibitors Featuring P3-Heterocycles with P1-Bicyclic Arginine Surrogates”, Bioorganic & Medicinal Chemistry Letters: 12 2925-2930 (2002).
Dumas, “Protein Kinase Inhibitors: Emerging Pharmacophores 1997-2001”, Expert Opinion on Therapeutic Patents (2001) 11(3): 405-429.
Patel, et al., “Unsymmeterical Cyclic Ureas As HIV-1 Protease Inhibitors: Novel Biaryl Indazoles as P2/P2′ Substituents,” Bioorganic & Medicinal Chemistry Letters, 9:3217-3220 (1999).
File Chemical Abstracts, STN Caesar Accession No. 1189, AN 52:25500, Gazzetta Chimica Italiana, 87, 931-948, (1957).
File Chemical Abstracts, STN Caesar Accession No. 1145, AN 132:122591, Bioorganic & Medicinal Chemistry Letters, 9(22), 3217-2330, (1999).
Aronov Alex
Lauffer David J.
Li Huan Qiu
Li Pan
Tomlinson Ronald Charles
Aulakh Charanjit S
Che Jennifer G.
Vertex Pharmaceuticals Incorporated
LandOfFree
Indazolinone compositions useful as kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indazolinone compositions useful as kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indazolinone compositions useful as kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4167470